Axogen Dividendos y recompras
Dividendo controles de criterios 0/6
Axogen no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-5.7%
Rendimiento de la recompra
| Rendimiento total para el accionista | -5.7% |
| Rendimiento futuro de los dividendos | n/a |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
Actualización de narrativa • Aug 04
AXGN: Raised 2026 Guidance And Q2 Execution Will Support Further Upside
Axogen's updated analyst price target has increased from $50.78 to $53.22 as analysts respond to stronger Q2 results, higher revenue and margin assumptions, and a lower projected P/E multiple. Together, these factors support a modestly higher valuation.Seeking Alpha • Aug 03
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Summary Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance’s FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity. AXGN trades at a premium valuation, requiring sustained 15-20%+ growth and operating leverage; execution, margin expansion, and confirmatory trial results are critical to justifying current multiples. Read the full article on Seeking AlphaArtículo de análisis • Aug 01
Analysts Have Made A Financial Statement On Axogen, Inc.'s (NASDAQ:AXGN) Second-Quarter Report
Investors in Axogen, Inc. ( NASDAQ:AXGN ) had a good week, as its shares rose 6.9% to close at US$42.21 following the...Actualización de narrativa • Jun 14
AXGN: Lower Discount Rate And 2026 Guidance Will Support Further Upside
Axogen's analyst price target has been raised in a series of Street updates, with increases such as $5, $7, $8, $10 and $11, as analysts point to refined discount rate and earnings assumptions while keeping fair value and long term growth forecasts broadly consistent. Analyst Commentary Recent Street research on Axogen clusters around a similar narrative, with price target changes framed around adjustments to discount rates and earnings assumptions rather than sweeping changes to long term growth views or fair value frameworks.Actualización de narrativa • May 31
AXGN: Lower Risk Assumptions And 2026 Guidance Will Drive Upside Potential
Axogen's updated analyst price target is unchanged in this model at $50.78. Recent target increases from multiple firms are generally tied by analysts to refined discount rate assumptions and updated long term P/E expectations, rather than shifts in projected revenue growth or profit margins.Actualización de narrativa • May 04
AXGN: BLA Approval And New Market Entry Will Drive Upside Potential
Axogen's analyst price target has been raised from $41.22 to $50.78, with analysts pointing to updated assumptions around fair value, revenue growth, profit margins and recent Street research highlighting the impact of Avance Nerve Graft's BLA approval and commercial expansion opportunities. Analyst Commentary Recent Street research around Axogen clusters around the impact of Avance Nerve Graft's BLA approval, expanded market exposure and revised fair value assumptions, with a series of price target moves anchoring the discussion.Artículo de análisis • Apr 30
Axogen, Inc. (NASDAQ:AXGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$50.78
It's been a pretty great week for Axogen, Inc. ( NASDAQ:AXGN ) shareholders, with its shares surging 12% to US$41.77 in...Actualización de narrativa • Apr 18
AXGN: BLA Approval And Market Expansion Will Shape Balanced Risk Reward Outlook
Narrative Update on Axogen Axogen's updated fair value estimate has moved by about $0.67, with analysts pointing to higher price targets around $40 to $42, supported by Avance Nerve Graft's FDA BLA approval, broader market expansion plans, and recent coverage highlighting its differentiated position in peripheral nerve repair. Analyst Commentary Recent research commentary on Axogen has focused heavily on the FDA BLA approval for Avance Nerve Graft, higher price targets around the low $40 range, and the company’s focus on expanding into new clinical markets.Actualización de narrativa • Apr 01
AXGN: BLA Approval Will Support Broader Peripheral Nerve Repair Adoption
Narrative Update on Axogen Axogen's analyst price targets have shifted higher into the low $40s, with analysts pointing to recent FDA BLA approval for Avance Nerve Graft, broader market expansion plans, and reduced risk following an equity raise as key supports for their updated views. Analyst Commentary Recent research on Axogen has centered on the FDA BLA approval for Avance Nerve Graft, the equity raise, and the company’s focus on peripheral nerve repair.Actualización de narrativa • Mar 17
AXGN: BLA Approval Should Support Wider Nerve Repair Market Adoption
Analysts have nudged Axogen's fair value estimate higher, with the blended price target moving from about $39.20 to roughly $40.56 as recent FDA BLA approval for Avance Nerve Graft and broader market expansion potential support more constructive views on growth and profitability. Analyst Commentary Recent research updates cluster around a more constructive view of Axogen following FDA BLA approval for Avance Nerve Graft and a clearer path to broader market coverage and adoption.Actualización de narrativa • Mar 03
AXGN: BLA Approval And Equity Raise Will Support 2026 Nerve Repair Rollout
Axogen's analyst price target moves higher, with recent Street research pointing to a range of $40 to $42 as analysts highlight the FDA BLA approval for Avance Nerve Graft, expanded market opportunities, and expectations for sustained revenue growth and improving profitability. Analyst Commentary Recent research updates cluster around the FDA BLA approval for Avance Nerve Graft and how it could influence Axogen's growth, profitability, and valuation over time.Actualización de narrativa • Feb 17
AXGN: Follow On Equity Raises Will Support Bullish 2025 Outlook
Analysts have slightly trimmed their average price target for Axogen, now reflecting a modestly lower assumed future P/E multiple while keeping fair value estimates around $37.33 and making only marginal adjustments to the discount rate, revenue growth, and profit margin assumptions. What's in the News Axogen filed a follow on equity offering of up to $85 million in common stock, providing additional access to equity capital if the company chooses to proceed with the full amount.Actualización de narrativa • Feb 02
AXGN: FDA Approval And Capital Raises Will Shape 2025 Outlook
Analysts have nudged their price target for Axogen slightly higher to reflect a modest uptick in fair value estimates to about $37.33. This move is supported by marginally stronger assumptions for profit margins and a slightly lower discount rate, while other pricing inputs, such as future P/E expectations, remain roughly in line with prior views.Actualización de narrativa • Jan 19
AXGN: Q3 Execution And 2025 Outlook Will Support Higher Confidence
Analysts have nudged their fair value estimate for Axogen higher to US$37.00 from US$35.44, citing recent price target increases following Q3 outperformance and raised 2025 guidance as support for this updated view. Analyst Commentary Recent research updates cluster around Axogen's Q3 performance and refreshed 2025 outlook, with multiple price target revisions framing how analysts are thinking about valuation, growth, and execution risk.Actualización de narrativa • Jan 04
AXGN: Q3 Execution Will Support Confidence In Raised 2025 Outlook
Analysts have nudged their average price target on Axogen higher, lifting it by a few dollars per share into the mid 20 dollar range. They cite the company's Q3 sales beat, increased 2025 growth outlook, and continued confidence in its market development strategy as key drivers of sustained revenue expansion.Actualización de narrativa • Dec 14
AXGN: Market Development Progress Will Support Confidence In 2025 Outlook
Axogen's analyst price target has been raised materially, increasing from about $29 to roughly $35. Analysts cite a Q3 beat, an improved 2025 sales growth outlook of at least 19 percent year over year, and continued confidence that the company’s market development strategy will support faster revenue growth even as margins normalize.Actualización de narrativa • Nov 30
AXGN: Execution And Upgraded Outlook Will Support Measured Momentum Ahead
Analysts have raised their price target for Axogen by $0.63 to $29.13, citing better-than-expected third-quarter performance and a strengthened sales outlook that is expected to drive anticipated growth in the coming years. Analyst Commentary Bullish analysts have responded positively to Axogen's recent performance and guidance updates.Artículo de análisis • Nov 27
Returns Are Gaining Momentum At Axogen (NASDAQ:AXGN)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Actualización de narrativa • Nov 16
AXGN: Strong Execution Will Drive Revenue Momentum With Upgraded 2025 Outlook
Axogen’s analyst price target has increased from $27.38 to $28.50 per share. Analysts cite strong quarterly results and higher fiscal 2025 growth guidance as supporting factors for this upward revision.Artículo de análisis • Nov 04
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 30% Price Jump
Axogen, Inc. ( NASDAQ:AXGN ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Actualización de narrativa • Oct 31
AXGN: Strong Sales Momentum And Upcoming FDA Decision Will Drive Future Upside
Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.Artículo de análisis • Sep 12
Axogen (NASDAQ:AXGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Jul 23
Axogen, Inc.'s (NASDAQ:AXGN) Shares Leap 29% Yet They're Still Not Telling The Full Story
Those holding Axogen, Inc. ( NASDAQ:AXGN ) shares would be relieved that the share price has rebounded 29% in the last...Nueva narrativa • May 29
BLA Approval Will Secure 12-Year Exclusive Market Position
Anticipated product approval and targeted commercial expansion are driving increased market share, revenue growth, and improved profitability potential.Artículo de análisis • May 10
Axogen, Inc. (NASDAQ:AXGN) Might Not Be As Mispriced As It Looks After Plunging 32%
Axogen, Inc. ( NASDAQ:AXGN ) shareholders that were waiting for something to happen have been dealt a blow with a 32...Artículo de análisis • Apr 17
Would Axogen (NASDAQ:AXGN) Be Better Off With Less Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Mar 26
Shareholders Should Be Pleased With Axogen, Inc.'s (NASDAQ:AXGN) Price
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Axogen, Inc. ( NASDAQ:AXGN ) is a stock to...Artículo de análisis • Jan 14
Is Axogen (NASDAQ:AXGN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de AXGN han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de AXGN han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Axogen vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (AXGN) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.1% |
| Media de la industria (Medical Equipment) | 2.0% |
| Analista de previsiones (AXGN) (hasta 3 años) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de AXGN en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de AXGN en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de AXGN para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que AXGN no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 20:56 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Axogen, Inc. está cubierta por 19 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |
| Christopher Pasquale | Guggenheim Securities, LLC |